Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291369 | 0.83 | NOTUM (0.43) | PPARANOTUMRAB9ANPC1KDM4E | |
| SCHEMBL3290943 | 0.82 | NOTUM (0.42) | PPARANOTUMRAB9ANPC1KDM4E | |
| SCHEMBL1048006 | 0.81 | TP53 (0.49) | RAB9ANPC1KDM4EPOLBALDH1A1 | |
| SCHEMBL1051303 | 0.81 | ALDH1A1 (0.51) | PPARANOTUMRAB9ANPC1KDM4E | |
| SCHEMBL1045451 | 0.79 | MAPT (0.49) | PPARANOTUMRAB9ANPC1KDM4E | |
| SCHEMBL3294077 | 0.79 | POLB (0.55) | NPC1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL1051419 | 0.79 | KDM4E (0.60) | PPARARAB9ANPC1KDM4EPPARG | |
| SCHEMBL4830153 | 0.79 | HSD17B10 (0.53) | PPARAKDM4EPOLBALDH1A1HPGD | |
| SCHEMBL4830096 | 0.79 | TARBP2 (0.50) | PPARARAB9ANPC1KDM4EPPARG | |
| SCHEMBL1049626 | 0.79 | ALDH1A1 (0.51) | PPARARAB9ANPC1KDM4EPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7399777-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| EP-1425014-B1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6884812-B2 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-26 | — | — | US | disclosed |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1425014-A1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-6624185-B2 | Drugs at least one lipid- or triglyceride-lowering active compound; and carriers for lipid metabolism | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-09-23 | — | — | US | disclosed |
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-31 | — | — | US | disclosed |
| WO-2003020269-A1 | DIARYL CYCLOALKYL DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS PPAR ACTIVATORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144332-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals | PNLIP, LIPC, APOB | PPARA 383/4885NOTUM 524/4885RAB9A 2274/4885 |
| US-20040122069-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, APOB | PPARA 365/4885NOTUM 604/4885RAB9A 2390/4885 |
| US-20050267177-A1 | Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals | PNLIP, LIPC, LIPA | PPARA 345/4885NOTUM 529/4885RAB9A 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.